A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing

The WTD Steering Committee

Research output: Contribution to journalArticlepeer-review

Abstract

Testing for polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene is still a standard part of thrombophilia testing in many laboratories. However, it is clear that these polymorphisms are not risk factors for arterial or venous thrombosis and therefore should not be part of thrombophilia testing. Eliminating MTHFR from thrombophilia testing will reduce patient concerns and health care costs.

Original languageEnglish (US)
Article numbere12739
JournalResearch and Practice in Thrombosis and Haemostasis
Volume6
Issue number4
DOIs
StatePublished - May 2022

Keywords

  • guidelines
  • homocysteine
  • MTHFR
  • testing
  • thrombophilia

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing'. Together they form a unique fingerprint.

Cite this